For example, the GALAD score, which incorporates age, gender, AFP, AFP-L3, and DCP to assess probability of HCC in patients with chronic liver disease, has been validated in multiple patient populations [29–31]. This evidence concerns the gene AFP and hepatocellular carcinoma.